Abeona Therapeutics Inc.
ABEO
Key stats
- Open
- 2.28
- Day high
- 2.35
- Day low
- 2.22
- Previous close
- 2.30
- Volume
- 2.42M
- VWAP
- 2.29
- 52-week high
- 7.65
- 52-week low
- 2.22
- Market cap
- 141.77M
- Shares out
- 57.18M
- Employees
- 226
- Listed
- 1980
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
PHARMACEUTICAL PREPARATIONS · CLEVELAND, OH · abeonatherapeutics.com
Options · expiring Nov 20
Nov 12, 3:54 PM ET- Call open interest
- 65
- Put open interest
- 21
- Put/call
- 0.32
- At-the-money IV
- 177.6%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 3 call | 0.05 | Nov 10, 2:27 PM | 26 | 51 | 0.1% |
| 2 call | 0.80 | Nov 9, 3:40 PM | 11 | 12 | 177.6% |
| 3 put | 0.70 | Nov 12, 9:36 AM | 2 | 21 | 280.6% |
| 1 call | 3.56 | Oct 28, 11:05 AM | 1 | 2 | 0.1% |
| 1 put | — | — | 0 | 0 | — |
| 2 put | — | — | 0 | 0 | — |
Quarterly results
Massive · Aug 13, 2026| Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | Q3 2025 to Sep 30, 2025 | |
|---|---|---|---|---|
| Revenue | $11.38M | $8.72M | $5.42M | $0 |
| Gross profit | $7.20M | $6.02M | $4.38M | −$488.0K |
| Operating income | −$13.65M | −$23.03M | −$22.91M | −$24.02M |
| Net income | −$20.19M | −$17.07M | −$20.46M | −$5.16M |
| Diluted EPS | -0.35 | -0.30 | -0.22 | -0.10 |
| Operating cash flow | −$17.50M | −$19.80M | −$17.95M | −$21.19M |
| Assets | $179.51M | $198.49M | $219.57M | $231.09M |
| Liabilities | $51.45M | $53.55M | $60.35M | $59.86M |
| Equity | $128.06M | $144.94M | $159.22M | $171.23M |
Technicals
Massive · Nov 12, 2026- 50-day average4.77
- 200-day average5.41
- RSI (14 days)17.2
Short interest
Massive · Oct 30, 2026- Oct 30, 202616.88M shares · 21.7 days to cover
- Oct 15, 202617.21M shares · 12.7 days to cover
- Sep 30, 202616.88M shares · 11.6 days to cover
- Sep 15, 202615.75M shares · 12.0 days to cover
Splits
Massive · Jul 5, 2022- Jul 5, 20221-for-25
News coverage
No stories about Abeona Therapeutics Inc. right now.